Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 273 participants.
Also called NCT03349840
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 273 participants
- Registry
-
NCT03349840
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Qatar
- Registry status
- Terminated
Technical summary
Registry record NCT03349840. Randomized; no masking; primary purpose treatment. Start 2018-01-07 (actual); primary completion 2018-08-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan
- Condition
- Type2 Diabetes
- Intervention (Drug)
- Insulin Degludec U100
- Intervention (Drug)
- Insulin Glargine
- Lead sponsor
- Weill Cornell Medical College in Qatar
- Collaborator
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03349840- Content hash
671e2f8e7782420c730c5f37d8356a056f6f3aa64c607813bcb1a8afbc202970